Tags

Type your tag names separated by a space and hit enter

Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.

Abstract

BACKGROUND & AIMS

Irritable bowel syndrome (IBS) has been associated with disruptions to the intestinal microbiota, but studies have had limited power, coverage, and depth of analysis. We aimed to define microbial populations that can be used discriminate the fecal microbiota of patients with IBS from that of healthy subjects and correlate these with IBS intestinal symptom scores.

METHODS

The microbiota composition was assessed by global and deep molecular analysis of fecal samples from 62 patients with IBS patients and 46 healthy individuals (controls). We used a comprehensive and highly reproducible phylogenetic microarray in combination with quantitative polymerase chain reaction.

RESULTS

The intestinal microbiota of IBS patients differed significantly (P = .0005) from that of controls. The microbiota of patients, compared with controls, had a 2-fold increased ratio of the Firmicutes to Bacteroidetes (P = .0002). This resulted from an approximately 1.5-fold increase in numbers of Dorea, Ruminococcus, and Clostridium spp (P < .005); a 2-fold decrease in the number of Bacteroidetes (P < .0001); a 1.5-fold decrease in numbers of Bifidobacterium and Faecalibacterium spp (P < .05); and, when present, a 4-fold lower average number of methanogens (3.50 × 10(7) vs 8.74 × 10(6) cells/g feces; P = .003). Correlation analysis of the microbial groups and IBS symptom scores indicated the involvement of several groups of Firmicutes and Proteobacteria in the pathogenesis of IBS.

CONCLUSIONS

Global and deep molecular analysis of fecal samples indicates that patients with IBS have a different composition of microbiota. This information might be used to develop better diagnostics and ultimately treatments for IBS.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands.

    , , , , ,

    Source

    Gastroenterology 141:5 2011 Nov pg 1792-801

    MeSH

    Adult
    Aged
    Bifidobacterium
    Case-Control Studies
    Clostridium
    Feces
    Female
    Humans
    Irritable Bowel Syndrome
    Male
    Metagenome
    Microarray Analysis
    Middle Aged
    Phylogeny
    Ruminococcus

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    21820992

    Citation

    Rajilić-Stojanović, Mirjana, et al. "Global and Deep Molecular Analysis of Microbiota Signatures in Fecal Samples From Patients With Irritable Bowel Syndrome." Gastroenterology, vol. 141, no. 5, 2011, pp. 1792-801.
    Rajilić-Stojanović M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1792-801.
    Rajilić-Stojanović, M., Biagi, E., Heilig, H. G., Kajander, K., Kekkonen, R. A., Tims, S., & de Vos, W. M. (2011). Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology, 141(5), pp. 1792-801. doi:10.1053/j.gastro.2011.07.043.
    Rajilić-Stojanović M, et al. Global and Deep Molecular Analysis of Microbiota Signatures in Fecal Samples From Patients With Irritable Bowel Syndrome. Gastroenterology. 2011;141(5):1792-801. PubMed PMID: 21820992.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. AU - Rajilić-Stojanović,Mirjana, AU - Biagi,Elena, AU - Heilig,Hans G H J, AU - Kajander,Kajsa, AU - Kekkonen,Riina A, AU - Tims,Sebastian, AU - de Vos,Willem M, Y1 - 2011/08/05/ PY - 2011/05/08/received PY - 2011/07/22/revised PY - 2011/07/27/accepted PY - 2011/8/9/entrez PY - 2011/8/9/pubmed PY - 2012/1/21/medline SP - 1792 EP - 801 JF - Gastroenterology JO - Gastroenterology VL - 141 IS - 5 N2 - BACKGROUND & AIMS: Irritable bowel syndrome (IBS) has been associated with disruptions to the intestinal microbiota, but studies have had limited power, coverage, and depth of analysis. We aimed to define microbial populations that can be used discriminate the fecal microbiota of patients with IBS from that of healthy subjects and correlate these with IBS intestinal symptom scores. METHODS: The microbiota composition was assessed by global and deep molecular analysis of fecal samples from 62 patients with IBS patients and 46 healthy individuals (controls). We used a comprehensive and highly reproducible phylogenetic microarray in combination with quantitative polymerase chain reaction. RESULTS: The intestinal microbiota of IBS patients differed significantly (P = .0005) from that of controls. The microbiota of patients, compared with controls, had a 2-fold increased ratio of the Firmicutes to Bacteroidetes (P = .0002). This resulted from an approximately 1.5-fold increase in numbers of Dorea, Ruminococcus, and Clostridium spp (P < .005); a 2-fold decrease in the number of Bacteroidetes (P < .0001); a 1.5-fold decrease in numbers of Bifidobacterium and Faecalibacterium spp (P < .05); and, when present, a 4-fold lower average number of methanogens (3.50 × 10(7) vs 8.74 × 10(6) cells/g feces; P = .003). Correlation analysis of the microbial groups and IBS symptom scores indicated the involvement of several groups of Firmicutes and Proteobacteria in the pathogenesis of IBS. CONCLUSIONS: Global and deep molecular analysis of fecal samples indicates that patients with IBS have a different composition of microbiota. This information might be used to develop better diagnostics and ultimately treatments for IBS. SN - 1528-0012 UR - https://www.unboundmedicine.com/medline/citation/21820992/Global_and_deep_molecular_analysis_of_microbiota_signatures_in_fecal_samples_from_patients_with_irritable_bowel_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(11)01076-6 DB - PRIME DP - Unbound Medicine ER -